Fusidic Acid-d6
(Synonyms: Fusidate-d6; SQ-16603-d6) 目录号 : GC47386
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Fusidic acid-d6 is intended for use as an internal standard for the quantification of fusidic acid by GC- or LC-MS. Fusidic acid is a fusidane antibiotic originally isolated from F. coccineum.1 It is active against the Gram-positive bacteria S. aureus, S. pyogenes, C. diphtheriae, B. subtilis, and C. tetani (MIC50s = 0.01-20 µg/ml) but not the Gram-negative bacteria E. coli, S. typhimurium, and P. vulgaris or the fungi C. albicans and A. fumigatus (MIC50s = >100 µg/ml for all).2 Fusidic acid inhibits ribosomal recycling and protein translocation, processes mediated by elongation factor G (EF-G), in isolated E. coli ribosomes (IC50s = ~0.1 and ~200 µM, respectively).3 Topical administration of fusidic acid (2%) reduces the number of skin colony forming units (CFUs) and levels of TNF-α and IL-6 in a mouse model of methicillin-resistant S. aureus (MRSA) skin wound infection.4
1.Verbist, L.The antimicrobial activity of fusidic acidJ. Antimicrob. Chemother.25(Suppl. B)1-5(1990) 2.Godtfredsen, W.O., Jahnsen, S., Lorck, H., et al.Fusidic acid: A new antibioticNature193987(1962) 3.Savelsbergh, A., Rodnina, M.V., and Wintermeyer, W.Distinct functions of elongation factor G in ribosome recycling and translocationRNA15(5)772-780(2009) 4.Mohamed, M.F., and Seleem, M.N.Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infectionDrug Des. Devel. Ther.81979-1983(2014)
| Cas No. | N/A | SDF | |
| 别名 | Fusidate-d6; SQ-16603-d6 | ||
| Canonical SMILES | O[C@@H]1CC[C@@]2(C)[C@](CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@]4([H])[C@]3(C)C[C@H](OC(C)=O)/C4=C(C(O)=O)/CC/C=C(C([2H])([2H])[2H])/C([2H])([2H])[2H])([H])[C@@H]1C | ||
| 分子式 | C31H42D6O6 | 分子量 | 522.8 |
| 溶解度 | Chloroform: sparingly soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9128 mL | 9.5639 mL | 19.1278 mL |
| 5 mM | 0.3826 mL | 1.9128 mL | 3.8256 mL |
| 10 mM | 0.1913 mL | 0.9564 mL | 1.9128 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。